Proteostasis disruption and senescence in Alzheimer’s disease pathways to neurodegeneration

Brain Research, Journal Year: 2024, Volume and Issue: 1845, P. 149202 - 149202

Published: Aug. 30, 2024

Language: Английский

---

Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(6), P. 5929 - 5949

Published: June 13, 2024

Semaglutide (SEM), a glucagon-like peptide-1 receptor agonist, has garnered increasing interest for its potential therapeutic effects in neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s (PD). This review provides comprehensive description of SEM’s mechanism action preclinical studies these debilitating conditions. In animal models AD, SEM proved beneficial on multiple pathological hallmarks the disease. administration been associated with reductions amyloid-beta plaque deposition mitigation neuroinflammation. Moreover, treatment shown to ameliorate behavioral deficits related anxiety social interaction. SEM-treated animals exhibit improvements spatial learning memory retention tasks, evidenced by enhanced performance maze navigation tests novel object recognition assays. Similarly, PD, demonstrated promising neuroprotective through various mechanisms. These include modulation neuroinflammation, enhancement mitochondrial function, promotion neurogenesis. Additionally, improve motor function dopaminergic neuronal loss, offering disease-modifying strategies. Overall, accumulating evidence from suggests that holds promise approach AD PD. Further research is warranted elucidate underlying mechanisms translate findings into clinical applications devastating disorders.

Language: Английский

---

Brain Glucose Hypometabolism and Brain Iron Accumulation as Therapeutic Targets for Alzheimer’s Disease and Other CNS Disorders

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 271 - 271

Published: Feb. 19, 2025

Two common mechanisms contributing to multiple neurological disorders, including Alzheimer's disease, are brain glucose hypometabolism (BGHM) and iron accumulation (BIA). Currently, BGHM BIA both widely acknowledged as biomarkers that aid in diagnosing CNS distinguishing between disorders with similar symptoms, tracking disease progression. Therapeutics targeting can be beneficial treating neurocognitive symptoms. This review addresses the evidence for therapeutic potential of disorders. Intranasal insulin, which is anti-inflammatory increases cell energy, intranasal deferoxamine, reduces oxidative damage inflammation, represent promising treatments these mechanisms. Both targets AD other

Language: Английский

---

Exploring interdisciplinary perspectives on the implementation of personalized medicine and patient-orchestrated care in Alzheimer's disease: A qualitative study within the ABOARD research project

Journal of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Background The concepts of ‘ personalized medicine ’ and patient-orchestrated care in Alzheimer's disease (AD) lack standard conceptualization, which presents challenges for collaborative interdisciplinary care. Objective We explored the interpretations perspectives professionals involved work on a large-scale project, “ABOARD”, with aim to implement AD. Methods Semi-structured interviews were conducted 30 audio-recorded. Two researchers independently coded data inductively, followed by thematic analysis. Results According across different disciplinary backgrounds (mean age 45.7 years; 53.3% female), pertains relevant options that an individual has, informed biomedical psychosocial factors, whereas captures factors decision-making process. Professionals differed their views regarding its desirability feasibility. viewed as similar professionals, both involve personal preferences while ultimately assigning responsibility clinician. However, implementation persist, no differences found between clinicians other AD-related professionals. Conclusions AD have shared but Personal are seen part , not yet reflected definitions field beyond. Critical discussions existing doubts necessary . Multi-level changes needed concepts, warrants stakeholder involvement well support resources from entire field.

Language: Английский

---

Alzheimer’s Disease: Recent Developments in Pathogenesis, Diagnosis, and Therapy

Life, Journal Year: 2025, Volume and Issue: 15(4), P. 549 - 549

Published: March 27, 2025

As the leading cause of dementia, Alzheimer’s disease (AD) remains one most pressing global health challenges, affecting millions worldwide and placing an immense burden on healthcare systems caregivers [...]

Language: Английский

---

The Role of Phosphatidylethanolamine-Binding Protein (PEBP) Family in Various Diseases: Mechanisms and Therapeutic Potential

Progress in Biophysics and Molecular Biology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

---

Design, synthesis and anti-Alzheimer's disease activity evaluation of C-3 arylated huperzine A derivatives

Fitoterapia, Journal Year: 2024, Volume and Issue: 177, P. 106141 - 106141

Published: July 23, 2024

Language: Английский

---

Future perspectives on the clinics of Alzheimer's disease

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 217 - 232

Published: Oct. 25, 2024

Language: Английский

---

Design, Synthesis and Anti-Alzheimer's Disease Activity Evaluation of C-3 Arylated Huperzine a Derivatives

Published: Jan. 1, 2024

Language: Английский

---

Dementia and digital health

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 169 - 180

Published: Aug. 23, 2024

Language: Английский

---